Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark
Mint
The brief
Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
Reported by
Mint
This is a short headline brief. The complete report belongs to its publisher.
